{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:19:16Z","timestamp":1778591956802,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Patients receiving clozapine must undergo routine blood monitoring to screen for neutropenia, and to monitor for potential agranulocytosis. In Cork University Hospital, Cork, Ireland, clozapine is dispensed in the hospital pharmacy and the pharmacists are not aware of co-prescribed medicines, potentially impacting upon patient safety. The aim of this study was to examine the continuity of care of patients prescribed clozapine. A retrospective audit was conducted on patients attending the clozapine clinic at Cork University Hospital and assessed patients\u2019 (i) independent living, (ii) co-prescribed medicines and (iii) knowledge of their community pharmacists regarding co-prescribed clozapine. A list of prescribed medicines for each patient was obtained, and potential drug-drug interactions between these medicines and clozapine were examined using Lexicomp\u00ae and Stockley\u2019s Interaction checker. Secondary outcomes included patients\u2019 physical health characteristics, and a review of co-morbidities. Data were collected between the 29 May 2017 and 20 June 2017. Local ethics committee approval was granted. Patients were eligible for inclusion if they were receiving clozapine treatment as part of a registered programme, were aged 18 years or more, and had the capacity to provide written informed consent. Microsoft Excel was used for data analysis. Of 112 patients, (33% female; mean age (SD) 43.9 (11.3) years; 87.5% living independently\/in the family home) 86.6% patients reported that they were taking other prescribed medicines from community pharmacies. The mean (SD) number of co-prescribed medicines in addition to clozapine was 4.8 (4) per patient. Two thirds of community pharmacists were unaware of co-prescribed clozapine. Interactions with clozapine were present in all but 3 patients on co-prescribed medicines (n = 97). Lexicomp\u00ae reported 2.9 drug-drug interactions\/patient and Stockley\u2019s Interaction Checker reported 2.5 drug-drug interactions\/patient. Secondary outcomes for patients included BMI, total cholesterol, and HbA1c levels, which were elevated in 75%, 54% and 17% respectively. Patients prescribed clozapine did not receive a seamless service, between primary and secondary care settings. Community pharmacists were not informed of clozapine, prescribed for their patients, in two thirds of cases. Patients in this study were exposed to clozapine-related drug-drug interactions and hence potential adverse effects. This study supports reports in the literature of substandard management of the physical health of this patient group. This study shows that there is an opportunity for pharmacists to develop active roles in the management of all clozapine-related effects, in addition to their traditional obligatory role in haematological monitoring. This study supports the need for a clinical pharmacist to review inpatients commencing on clozapine, monitor for drug-drug interactions and provide counselling.<\/jats:p>","DOI":"10.3390\/pharmacy6010019","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T03:36:12Z","timestamp":1519702572000},"page":"19","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clozapine Patients at the Interface between Primary and Secondary Care"],"prefix":"10.3390","volume":"6","author":[{"given":"Marita","family":"Barrett","sequence":"first","affiliation":[{"name":"Pharmacy Department, Cork University Hospital, Cork T12 DC4A, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Keating","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Cork University Hospital, Cork T12 DC4A, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Lynch","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Cork University Hospital, Cork T12 DC4A, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Scanlon","sequence":"additional","affiliation":[{"name":"Adult Mental Health Unit, Cork University Hospital, Cork T12 DC4A, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Kigathi","sequence":"additional","affiliation":[{"name":"Adult Mental Health Unit, Cork University Hospital, Cork T12 DC4A, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidelma","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Adult Mental Health Unit, Cork University Hospital, Cork T12 DC4A, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sahm","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University College Cork, Cork T12 YN60, Ireland"},{"name":"Pharmacy Department, Mercy University Hospital, Cork T12 WE28, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"ref_1","first-page":"164","article-title":"Characterization of Admission Types in Medically Hospitalized Patients Prescribed Clozapine","volume":"58","author":"Leung","year":"2017","journal-title":"J. Consul. Liaison Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1192\/bjp.bp.113.142521","article-title":"Assessment and Treatment of Physical Health Problems Among People with Schizophrenia: National Cross-sectional Study","volume":"205","author":"Crawford","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.18773\/austprescr.2011.057","article-title":"Managing the Metabolic Adverse Effects of Antipsychotic Drugs in Patients with Psychosis","volume":"34","author":"Lambert","year":"2011","journal-title":"Aust. Presc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Knowles, S.A., McMillan, S.S., and Wheeler, A.J. (2016). Consumer Access to Clozapine in Australia: How Does This Compare to New Zealand and the United Kingdom?. Pharm. Pract., 14.","DOI":"10.18549\/PharmPract.2016.02.722"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Murphy, K., Coombes, I., Moudgil, V., Patterson, S., and Wheeler, A. (2017). Clozapine and Concomitant Medications: Assessing the Completeness and Accuracy of Medication Records for People Prescribed Clozapine Under Shared Care Arrangements. J. Eval. Clin. Pract.","DOI":"10.1111\/jep.12743"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/0004867415592957","article-title":"Clozapine in the community: Improved Access or Risky Free-for-all?","volume":"49","author":"Winckel","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pnp.156","article-title":"Audit of GP Practice Records of Patients Prescribed Clozapine","volume":"14","author":"Parker","year":"2010","journal-title":"Prog. Neurol. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.sapharm.2006.10.005","article-title":"Developing the Role of Pharmacists as Members of Community Mental Health Teams: Perspectives of Pharmacists and Mental Health Professionals","volume":"3","author":"Bell","year":"2007","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1447-0349.2012.00859.x","article-title":"Gaps in Health Care for the Somatic Health of Outpatients with Severe Mental Illness","volume":"22","author":"Schorr","year":"2013","journal-title":"Int. J. Ment. Health Nurs."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Heald, A., Livingston, M., Yung, A., and De Hert, M.A. (2017). Prescribing in Schizophrenia and Psychosis: Increasing Polypharmacy Over Time. Hum. Psychopharmacol., 32.","DOI":"10.1002\/hup.2579"},{"key":"ref_11","unstructured":"Taylor, D., Sutton, J., and Family, H.E. (2011). Evaluating the Pharmacist Provision of Clozapine Services, University of Bath."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.sapharm.2010.03.006","article-title":"New Zealand Community Pharmacists\u2019 views of Their Roles in Meeting Medicine-related Needs for People with Mental Illness","volume":"7","author":"Crump","year":"2011","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_13","unstructured":"WoltersKluwer (2017, August 07). Lexicomp\u00ae Drug Interactions. Available online: sit.ucc.ie UpToDate."},{"key":"ref_14","unstructured":"Preston, C.L. (2017, August 07). Stockley\u2019s Drug Interactions. Available online: sit.ucc.ie medicinescomplete."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/2279-042X.192461","article-title":"A Comparison of Five Common Drug-drug Interaction Software Programs Regarding Accuracy and Comprehensiveness","volume":"5","author":"Kheshti","year":"2016","journal-title":"J. Res. Pharm. Pract."},{"key":"ref_16","unstructured":"(2017, January 22). Summary of Product Characteristics Clozaril Ireland: Mylan. Available online: https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/LicenseSPC_PA0013-046-002_04112016145050.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemia","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_18","unstructured":"(2017, August 18). Information for Healthcare Professionals Regarding Diabetes, 2010. Available online: http:\/\/www.hse.ie\/eng\/services\/Publications\/topics\/Diabetes\/HbA1c_Information_for_Health_Care_Professionals_regarding_Diabetes.pdf."},{"key":"ref_19","unstructured":"(2017, August 18). Type 2 Diabetes in Adults: Management. Available online: https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/1-Recommendations."},{"key":"ref_20","unstructured":"Harkins, V. (2016). A Practical Guide to Integrated Type 2 Diabetes Care, Irish College of General Pracititioners."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/pb.bp.109.028753","article-title":"Improving Physical Health Monitoring in Secondary Care for Patients on Clozapine","volume":"35","author":"Bolton","year":"2011","journal-title":"Psychiatrist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1039856213498427","article-title":"Demonstrating the Effectiveness of Less Restrictive Care Pathways for the Management of Patients Treated with Clozapine","volume":"21","author":"Filia","year":"2013","journal-title":"R. Aust. N. Z. Coll. Psychiatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.9758\/cpn.2016.14.3.286","article-title":"A Questionnaire-based Study of the Views of Schizophrenia Patients and Psychiatric Healthcare Professionals in Japan about the Side Effects of Clozapine","volume":"14","author":"Takeuchi","year":"2016","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.pnpbp.2017.06.026","article-title":"Cigarette Smoking and Schizophrenia: A Specific Clinical and Therapeutic Profile? Results from the FACE-Schizophrenia Cohort","volume":"79","author":"Mallet","year":"2017","journal-title":"Prog. Neuro Psychopharmac. Boil. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.japh.2016.12.066","article-title":"Supporting Patients with Mental Illness: Deconstructing Barriers to Community Pharmacist Access","volume":"57","author":"Calogero","year":"2017","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.sapharm.2013.04.006","article-title":"Exploring the Relationship Between Mental Health Stigma, Knowledge and Provision of Pharmacy Services for Consumers with Schizophrenia","volume":"11","author":"Bell","year":"2015","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1176\/appi.ps.201100443","article-title":"Exposure to Potentially Dangerous Drug-drug Interactions Involving Antipsychotics","volume":"63","author":"Guo","year":"2012","journal-title":"Psychiatr. Serv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1099-1077(199701\/02)12:1<5::AID-HUP831>3.0.CO;2-4","article-title":"Clozapine Drug-Drug Interactions: A Review of the Literature","volume":"12","author":"Edge","year":"1997","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"ref_29","unstructured":"McNeilHealthcare(Ireland)Ltd. (2017, August 07). Domperidone-Important Safety Information from McNeil Healthcare (Ireland) Ltd. as Approved by the Irish Medicines Board 2014. Available online: http:\/\/www.hpra.ie\/homepage\/medicines\/safety-notices\/item?t=\/domperidone---important-safety-information-from-mcneil-healthcare-(ireland)-ltd.-as-approved-by-the-irish-medicines-board&id=c3d0f925-9782-6eee-9b55-ff00008c97d0."},{"key":"ref_30","first-page":"135","article-title":"Monitoring of Physical Health of Patients on Clozapine and Communication of Results with the Psychiatric Team","volume":"21","author":"Arif","year":"2013","journal-title":"Int. J. Pharm. Pract."},{"key":"ref_31","first-page":"8","article-title":"Clozapine Treatment in Patients Living in the Community","volume":"5","author":"Schembri","year":"2015","journal-title":"J. EuroMed Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shirazi, A., Stubbs, B., Gomez, L., Moore, S., Gaughran, F., Flanagan, R.J., MacCabe, J.H., and Lally, J. (2016). Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060863"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40266-013-0144-2","article-title":"Adverse Effects of Clozapine in Older Patients: Epidemiology, Prevention and Management","volume":"31","author":"Bishara","year":"2014","journal-title":"Drugs Aging"},{"key":"ref_34","unstructured":"NHS (2017, August 02). Stepping forward to 2020\/21: The Mental Health Workforce Plan for England 2017. Available online: https:\/\/www.rcpsych.ac.uk\/pdf\/FYFV%20Mental%20health%20workforce%20plan%20for%20England%20FINAL.pdf."},{"key":"ref_35","first-page":"56","article-title":"Providing Clozapine in community pharmacy","volume":"35","author":"Knowles","year":"2016","journal-title":"Aust. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ni Dhubhlaing, C., Young, A., and Sahm, L.J. (2017). Impact of Pharmacist Counselling on Clozapine Knowledge. Schizophr. Res. Treat., 2017.","DOI":"10.1155\/2017\/6120970"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/6\/1\/19\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:56:25Z","timestamp":1760194585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/6\/1\/19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["pharmacy6010019"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy6010019","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]}}}